Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 740-744, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (14)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dethy, S.
Right arrow Articles by Hildebrand, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dethy, S.
Right arrow Articles by Hildebrand, J.
Related Collections
Right arrow Drug Monitoring and Toxicology
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 1997;43:740-744.)
© 1997 American Association for Clinical Chemistry, Inc.

Articles

Microdialysis-HPLC for plasma levodopa and metabolites monitoring in parkinsonian patients

Sophie Dethy1,2,a, Marie Aline Laute1, Nadège Van Blercom1, Philippe Damhaut2, Serge Goldman2 and Jerzy Hildebrand1

1 Service de Neurologie and
2 PET/Biomedical Cyclotron Unit, ULB-Hôpital Erasme, Brussels, Belgium.
a Address correspondence to this author at: Service de Neurologie, ULB-Hôpital Erasme, 808, route de Lennik, B-1070 Brussels, Belgium. Fax (32–2) 555-4701; e-mail sdethy{at}ulb.ac.be

We used in vitro microdialysis-HPLC to determine L-3,4-dihydroxyphenylalanine (L-DOPA) and its metabolites in plasma of patients with advanced Parkinson disease. Blood samples and clinical evaluations were obtained 0, 30, 60, 90, 120, and 150 min after oral administration of carbidopa/L-DOPA (25/100 mg, 12.5/125 mg, and 50/200 mg). In vitro recoveries for L-DOPA and metabolites ranged from 22% to 36%. Linear correlation was found between metabolite concentrations in the dialysate and in the surrounding medium. There was a significant positive correlation between L-DOPA dose and plasma concentration of L-DOPA and homovanillic acid (P <0.04). Clinical response was maximum 60 min after L-DOPA administration. Threshold L-DOPA plasma concentration averaged 7.74 ± 3.3 µmol/L. Motor effect is longer with the highest L-DOPA peak concentration (P <0.01). Microdialysis-HPLC is readily applicable, reproducible, and allows monitoring of plasma L-DOPA and metabolites in parkinsonian patients.


Key Words: indexing terms: Parkinson disease • levodopa • catecholamines




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
N. Dizdar, A. Kullman, B. Norlander, J.-E. Olsson, and B. Kagedal
Human Pharmacokinetics of L-3,4-Dihydroxyphenylalanine Studied with Microdialysis
Clin. Chem., October 1, 1999; 45(10): 1813 - 1820.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
G. M. d'Eril, R. Moratti, and E. Perucca
Total and Non-Protein-bound Fractions of 3,4-Dihydroxyphenylalanine
Clin. Chem., April 1, 1998; 44(4): 895 - 895.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.